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Stem Cell Transplantation • Brief Report
Severe combined immunodeficiencies (SCID) are commonly fatal early in life. Adequate
diagnosis and rapid institution of treatment, such as allogeneic stem cell transplanta-
tion (SCT), is essential. Several studies demonstrated that reconstitution of B-cell func-
tion after SCT is better in B-positive SCID than in B-negative SCID. We demonstrate that
B-cell reconstitution in a B-negative SCID patient due to an Artemis mutation required
the elimination of the autologous precursor-B-cells in bone marrow, probably to create
physical space in the precursor-B-cell niches. Apparently, occupation of the precursor-
B-cell niches is a potential dominant factor influencing repopulation of a functional B-
cell compartment in B-negative SCID.
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Severe combined immunodeficiencies(SCID) constitute a heterogeneous groupof inherited disorders, which are charac-
terized by the absence of T cells accompanied
by the absence of either B cells or NK cells
depending on the SCID category. SCID result
in severe impairment of both cellular and
humoral immunity,1 and in the absence of
treatment lead to death during infancy due to
persistent and severe infections with oppor-
tunistic micro-organisms. Stem cell transplan-
tation (SCT) is the current treatment and pro-
duces a survival rate of around 80%; gene ther-
apy has been explored for some SCID condi-
tions.2-4 Immunologically, two major cate-
gories of SCID can be identified. The first cat-
egory comprises B-positive SCID, associated
with mutations in IL2RG or JAK3 (T–B+NK–
SCID), or with mutations in IL7RA (T–B+NK+
SCID).1,5 The second category comprises B-
negative SCID (T–B–NK+SCID), which are
mainly due to defects in V(D)J recombination
of immunoglobulin (Ig) and T-cell receptor
(TCR) genes. In approximately 70% of these
patients, mutations are found in the RAG1 and
RAG2 genes;6,7 and a subset of the remaining
patients show hypersensitivity to ionizing
radiation and have mutations in Artemis or
LIG4.8-13 In retrospective studies, it was
demonstrated that the results of HLA non-
identical T-cell-depleted SCT were significant-
ly better in patients with B-positive SCID than
in those with B-negative SCID.2,14,15 The
reduced survival of B-negative SCID patients
appeared to be associated with a lower rate of
engraftment (particularly in the absence of a
conditioning regimen), a higher frequency of
chronic graft-versus-host disease (GVHD),
increased severity of acute GVHD, and a slow-
er and less complete recovery of T/B immune
function.2,14,15 In patients with B-negative SCID,
engraftment of T-cell depleted bone marrow
and post-SCT restoration of B-cell function
might be increased through the use of a mye-
loablative conditioning regimen.2,14 The latter
observation has also specifically been made
concerning children transplanted for SCID due
to an Artemis gene defect.16
Detailed flow cytometric immunopheno-
typing of the precursor B cells in bone marrow
has shown that in healthy children and B-pos-
itive SCID patients, pro-B-cells and pre-B-I
cells represent 20% to 25% of the precursor B-
cell compartment, which also contains small
and large pre-B-II cells and immature B-cells.
However, in B-negative SCID patients (includ-
ing those with radiosensitive SCID with
Artemis mutations) pro-B-cells and pre-B-I cells
account for 95 to 100% of this compart-
ment.9,17,18 Since the total size of the precursor
B-cell compartment in B-negative SCID is not
smaller than in healthy children, it can be con-
cluded that the earliest stages of B-cell devel-
opment completely occupy the precursor B-
cell niches.9,19
Based on these observations, we hypothe-
sized that failure of B-cell reconstitution in B-
negative SCID patients after SCT might be
caused by lack of physical space in the bone
marrow due to the presence of a high frequen-
cy of early precursor B-cells (pro-B and pre-B-
I), which strongly adhere to their niches and
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which need to be eradicated by pre-SCT conditioning reg-
imens. We studied an Artemis-deficient SCID patient, who
did not show circulating mature B-cells after being trans-
planted without conditioning. Re-transplantation with
reduced intensity conditioning resulted in reconstitution
of a functional B-cell system. These observations are in
line with our hypothesis.
Case report
A female patient was referred at the age of 5 months for
failure to thrive and dyspnea. She had interstitial pneumo-
nia caused by Pneumocystis carinii and cytomegalovirus.
Treatment with cotrimoxazole and ganciclovir induced
recovery. Immunological studies revealed hypogamma-
globulinemia, absence of B-lymphocytes, decreased num-
bers of T-lymphocytes, but normal NK-cell counts. Her T-
cells appeared to be of maternal origin due to maternal
engraftment. The diagnosis of SCID was made and we
identified a homozygous G47T mutation in exon 5 of the
Artemis gene.9
At the age of 7 months, the girl received a non-T-cell
depleted bone marrow graft from her HLA-identical
brother without infusion of antithymocyte globulin or
conditioning. After an uneventful post-transplantation
course, a gradual rise in donor T-cells occurred and mater-
nal T-cells gradually disappeared within 1 year. There
were increases in the numbers of CD4-positive naïve T-
cells as well as in CD8-positive T-cells (Figure 1). Mono-
cytes, granulocytes and NK cells remained of host origin.
B cells continued to be absent and the patient was depend-
ent on immunoglobulin substitution. Therefore, at the age
of 38 months she received a second non-T-cell-depleted
bone marrow graft from the same donor. Conditioning
consisted of busulfan 2 mg/kg at days -3 and -2. This
reduced intensity conditioning did not result in neutrope-
nia, anemia or thrombocytopenia. The start of B-cell
reconstitution was observed at 1 month after the second
SCT and the absolute number of B-cells increased to sub-
normal levels (0.13×109/L) by 5 months after the trans-
plant. Eight months post-SCT chimerism analysis showed
that B and T cells were exclusively of donor origin, where-
as NK cells, monocytes and granulocytes were of recipient
origin. Most importantly, the girl developed normal IgG
and IgM serum levels, but no IgA. Upon vaccination she
developed normal antibody titers against diphtheria,
tetanus toxoid, poliomyelitis and Haemophilus influenzae.
Figure 1. Absolute numbers of lympho-
cytes. A. Absolute numbers of CD3+ T-
lymphocytes, CD19+ B-lymphocytes
and CD3–/CD56+ NK cells during the
course of transplantation. The time
points of SCT are indicated with
arrows. B. Absolute numbers of differ-
ent T-cell subsets (CD4, CD8, naïve
CD4+/CD45RA+ and effector/memory
CD4+/CD45RO+).
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Design and Methods
Flow cytometry
The precursor-B-cell compartment was analyzed at
diagnosis, 18 months after the first SCT and 7 months
after the second SCT.9 From the post-SCT bone marrow
samples four CD19-positive precursor-B-cell subsets were
sorted with a FACS Digital Vantage (DiVa) cell sorter (BD
Biosciences, Santa Clara, CA, USA) after four-color stain-
ing with CD34-FITC, CD20-PE (Leu-16), CD19-PerCP,
CD10-APC (HI10a) (BD Biosciences): (i) pre-B-I
(CD34+CD10+CD20–), (ii) pre-B-II large (CD34–CD10+
CD20–), (iii) pre-B-II small (CD34-CD10+CD20+), and (iv)
immature B-cells (CD34-CD10+CD20++).20
Chimerism analysis
DNA was extracted from the sorted cell fractions using
20 µL lysis buffer (10 mMTris-HCl (pH 7.6), 50 mMNaCl,
6.25 mM MgCl2, 0.045% NP40, 0.45% Tween-20). One
microliter of Prot K (20 mg/mL) was added followed by
incubation overnight at 56°C and inactivation by incuba-
tion at 95°C for 15 minutes. The chimerism status was
determined using the PowerPlex16 kit (Promega,Madison,
WI, USA).
Results and Discussion
Reconstitution of B-cell function after SCT is more com-
mon in B-positive SCID patients than in B-negative SCID
ones.2,15 The origin (host or donor) of peripheral blood B-
cells in B-positive SCID patients after SCT will have an
impact on B-cell function, but is often not reported. We
hypothesized that the impaired B-cell reconstitution in B-
negative SCID patients after SCT might be caused by lack
of physical space in the precursor B-cell compartment in
bone marrow due to the presence of a high frequency of
early precursor B cells (pro-B and pre-B-I), which probably
adhere tightly to their breeding sites.
We describe an Artemis-deficient SCID patient, who ini-
tially received a SCT without conditioning and did not
show B-cell reconstitution in the peripheral blood. This
patient was re-transplanted following conditioning con-
sisting of a low dose of busulfan. The precursor B-cell
compartment in the bone marrow was analyzed at diag-
nosis, as well as after the first and second transplant.9 At
diagnosis we observed a complete block in B-cell matura-
tion before the pre-B-II cell stage. After the first SCT, the
precursor B-cell compartment showed an incomplete
block with the presence of low proportions of cells at the
pre-B-II cell and immature B-cell stages. After the second
SCT, the composition of the precursor-B-cell compartment
was normal, being comparable to that of age-matched
healthy controls (Figure 2). The four CD19-positive pre-
cursor B-cell subsets were sorted from bone marrow after
the first and second transplants for chimerism analysis.
After the first SCT, all pre-B-I cells and most pre-B-II and
immature B-cells were of host origin. The more mature
precursor-B-cells constituted a reduced fraction of the pre-
cursor-B-cell compartment and only a small proportion of
these cells were of donor origin (Figure 3). Chimerism
analysis of the four CD19-positive precursor B-cell subsets
after the second SCT showed that less than 10% of the
pre-B-I cells remained of recipient origin and that the pre-
B-II large, pre-B-II small, and immature B-cell fractions
were completely donor derived (Figure 3). After the sec-
ond SCT, peripheral reconstitution of functional mature B-
cells was observed based on the absolute number of B-
cells, the development of normal IgG and IgM serum lev-
els, and the development of specific antibodies upon re-
vaccination.
In summary, the absence of B-cell reconstitution after
the first SCT (without conditioning) could be explained by
the persistence of patient-derived precursor B cells in the
bone marrow. Recovery of donor-derived T cells was nor-
mal, so the absence of B-cell reconstitution could not be
explained by NK-cell-mediated rejection of donor stem
cells. The second SCT, preceded by conditioning with a
low dose of busulfan, resulted in a precursor B-cell com-
partment that was almost completely (>90%) of donor
origin, giving rise to functional peripheral B-cell reconstitu-
tion. Reduced conditioning, which is far less toxic than
myelo-ablative conditioning, was already sufficient to
eradicate the recipient precursor B-cell compartment and
to achieve normal outgrowth of the donor B-lineage cells.
Figure 2. Flow cytometric analysis of the
composition of the bone marrow precursor B-
cell compartment at diagnosis, and after the
first and second transplants. At diagnosis
only pro-B and pre-B-I cells were found with
<2% pre-B-II cells and immature B-cells.
Eighteen months after the first SCT (per-
formed at the age of 7 months) only 20-25%
pre-B-II small and immature B-cells were
detected, but 7 months after the second SCT
with conditioning (performed at the age of
38 months), the precursor-B-cell compart-
ment was found to have a completely normal
composition.
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These observations demonstrate that B-cell repopulation
in B-negative SCID patients requires removal of the
patient’s precursor-B-cells. Although there are many fac-
tors influencing engraftment in patients given SCT for
SCID, this single case illustrates that eradication of the
patient’s precursor-B-cells is one of the potentially critical
factors in B-negative SCID. We are currently performing a
multi-center prospective study to further confirm our
hypothesis.
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Figure 3. Polymerase chain-reaction-based
chimerism analysis of DNA isolated from the
different precursor B-cell subpopulations in BM
after the first and second SCT. After the initial
SCT, virtually all precursor B-cells were still of
patient origin except for a small proportion of
the pre-B-II (small and large) and immature B
cells, which were of donor origin. The second
SCT resulted in a virtually complete donor-
derived precursor B-cell compartment, except
for a small fraction (<10%) of the pro-B-cells,
which were still of recipient origin. The dis-
played PowerPlex16 STR marker is Penta E.
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